GeneDx Holdings Affirms FY2026 Sales Guidance of $475.000M-$490.000M vs $478.367M Est
GeneDx Holdings (NASDAQ:WGS) affirms FY2026 sales outlook from $475.000 million-$490.000 million to $475.000 million-$490.000 million vs $478.367 million estimate.
GeneDx said their expected sales for next year will stay the same as they promised before—between $475 million and $490 million. This shows the company feels confident about sticking to their plan, even though some people thought they might do a tiny bit better.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.